EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma

Peng Zhang iD, Changjuan Tao, Ye Lu, Peijing Li, Xing Wang, Yujie Dai, Yun Xi, Takaya Shimura, Xinfang Li, Jianmin Fang, Liu Yang, Dawei He und 1 weitere

Advanced Science · 2024-08 · 11 (30)

DOI: 10.1002/advs.202400203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 14.06.2024. Verfasst von Peng Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, 310022, China. Hauptthemen laut MEDLINE: Intercellular Adhesion Molecule-1, Melanoma, Immunoconjugates, Epigenesis, Genetic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Agricultural and Social Development Research Project of Hangzhou Muncipal Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic benefits and underlying biomechanism(s) of antibody drug conjugates (ADC) in combination with other targeted therapeutics are largely unknown. Here, the synergy between ADC and epigenetic drug decitabine (DAC), a clinically approved DNA methylation inhibitor, in multiple preclinical models of melanoma specifically investigated. Mechanistically, the underlying biomechanisms of how DAC cooperatively worked with ICAM1 antibody conjugated DNA topoisomerase I inhibitor DXd (I1‐DXd) is elucidated. DAC treatment significantly enhanced anti‐tumor efficacy of I1‐DXd by upregulating antigen expression, enhancing antibody internalization and potentiating tumor sensitivity by epigenetically reprogramming of melanoma. Meanwhile, I1‐DXd/DAC combination also exerted regulatory effects on tumor microenvironment (TME) by enhancing tumor infiltration of innate and adaptive immune cells and improving penetration of ADCs with a boosted antitumor immunity. This study provides a rational ADC combination strategy for solid tumor treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intercellular Adhesion Molecule-1MelanomaImmunoconjugatesEpigenesis, GeneticDecitabineDisease Models, AnimalAnimalsMiceTumor MicroenvironmentCell Line, TumorHumans

Stichwörter der Autor:innen

ICAM1antibody drug conjugatedecitabinemelanomatargeted therapy

Substanzen

Intercellular Adhesion Molecule-1ImmunoconjugatesDecitabine

Autor:innen und Institutionen

  • Department of Medical Oncology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, 310022, China.
  • Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.
  • Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
  • Department of Radiation Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China.
  • Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China.
  • Department of Head and Neck Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China.

ORCID-Profile: Peng Zhang, Peng Guo

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Agricultural and Social Development Research Project of Hangzhou Muncipal Science and Technology Bureau
  • Natural Science Foundation of Zhejiang Province, China
  • Medical and Health Science and Technology Project of Zhejiang Province, China
  • Wujieping Science Foundation of China
  • Medical Science and Technology Project of Zhejiang Province
  • Science Fund for Distinguished Young Scholars of Zhejiang Province

Zitieren

APA

Zhang, P., Tao, C., Lu, Y., Li, P., Wang, X., Dai, Y., Xi, Y., Shimura, T., Li, X., Fang, J., Yang, L., He, D., & Guo, P. (2024). Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma. Advanced Science, 11(30). https://doi.org/10.1002/advs.202400203

Vancouver

Zhang P, Tao C, Lu Y, Li P, Wang X, Dai Y, et al. Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma. Advanced Science. 2024;11(30). doi:10.1002/advs.202400203

BibTeX
@article{Zhang2024,
  author = {Zhang, Peng and Tao, Changjuan and Lu, Ye and Li, Peijing and Wang, Xing and Dai, Yujie and Xi, Yun and Shimura, Takaya and Li, Xinfang and Fang, Jianmin and Yang, Liu and He, Dawei and Guo, Peng},
  title = {Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {30},
  doi = {10.1002/advs.202400203}
}
Kostenlos starten →